We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Abbott and AstraZeneca announced today a collaboration to co-develop and market a combination treatment that will target all three important blood lipids — LDL-C "bad" cholesterol, HDL-C "good" cholesterol, and triglycerides — in one single pill as part of a comprehensive treatment regimen.
Dendrite International, Inc., a provider of pharmaceutical industry solutions, has recently announced that Schering Corporation, has signed a five-year agreement to enhance VISION, its sales force effectiveness (SFE) and business planning solution, for its U.S.-based pharmaceutical field sales organization.
Despite high profile events such as the industry's showcase BIO 2006 in April and the annual meeting of the American Society of Clinical Oncology (ASCO) in June, they failed to generate any "buzz" for biotech investors in the second quarter.
A new medication that reduces the craving for cigarettes and abates withdrawal symptoms appears to be more effective in helping people break the smoking habit than the best therapy currently available, the nicotine-replacement drug bupropion, according to three studies published Tuesday.
Norwood Abbey Ltd advises that its subsidiary Norwood Immunology Limited, the company focussed on the rejuvenation of the immune system, has announced the completion of the Melbourne pilot exploratory clinical study in cancer patients undergoing chemotherapy and bone marrow transplantation (BMT).
Manufacturing violations cited in a June 15 FDA warning letter to Ranbaxy Laboratories could result in a hold on some of the company's new drug applications (NDAs) and a U.S. ban on importation of others.
Pfizer will sell its consumer healthcare division to Johnson & Johnson (J&J) for $16.6 billion and focus on developing new drugs and acquiring new technology, according to announcements by both companies.
The FDA may not be doing all it can to ensure timely approval of generics and prevent brand companies from exploiting the citizen petition process to delay competition, according to two members of the U.S. Senate.
Ranbaxy has received approval from the US FDA to manufacture and market Cefprozil for Oral Suspension USP, 125 mg/5mL and 250 mg/5mL, said the company press release.